[Pulmonary fibrosis. Classification, diagnosis, therapy].
A new classification of the idiopathic interstitial pneumonia has recently been proposed, defining idiopathic pulmonary fibrosis (IPF) more rigorously and in contrast to further subentities. The new classification is of prognostic and clinical relevance. Diagnosis requires a combined clinical, radiological and pathological effort. In patients with characteristic clinical and HR-CT findings, the diagnosis of IPF can be made with sufficient confidence without surgical lung biopsy. Recent evidence suggests that the primary pathogenetic event in IPF involves epithelial injury and abnormal wound heeling. This explains the ineffectiveness of the usual anti-inflammatory therapy in the majority of patients. Since no antifibrotic drugs are available at present, the recommended standard therapy is a combination of prednisone with azathioprine or cyclophosphamide. New antifibrotic molecules are already tested in clinical trials.
Costabel
U
U
Abteilung Pneumologie/Allergologie, Ruhrlandklinik Essen. erj.costabel@t-online.de
Guzman
J
J
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008168:Lung / Q000473:pathology; D011379:Prognosis; D011658:Pulmonary Fibrosis / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D012307:Risk Factors; D036542:Tomography, Spiral Computed
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents